Relaterede / Kontaktpersoner
Relaterede / Nyheder
European Commission Grants Marketing Authorization for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Pressemeddelelser • Sep 26, 2014 08:42 CEST
The European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers – chronic lymphocytic leukemia and follicular lymphoma. "Zydelig is a welcomed treatment option that offers a new approach in the management of these cancers," said Professor Peter Hillmen, Leeds Teaching Hospitals NHS Trust.
GILEAD PRESENTS FOLLOW-UP DATA FROM IDELALISIB (ZYDELIG®) REGISTRATIONAL STUDIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA, FOLLICULAR LYMPHOMA AND SMALL LYMPHOCYTIC LYMPHOMA
Pressemeddelelser • Dec 13, 2014 15:17 CET
-- Results Describing Long-Term Safety and Disease Control Presented at the 56th American Society of Hematology Annual Meeting --